Skip to main content

Year: 2025

Healthy Choice Wellness Provides Shareholder Update Highlighting Strategic Growth Drivers

HCWC expanding revenue streams while strengthening infrastructure and customer engagement  HOLLYWOOD, FL, March 12, 2025 (GLOBE NEWSWIRE) — Healthy Choice Wellness Corp. (“HCWC” or the “Company”) (NYSEAM: HCWC), a holding company operating 19 natural and organic grocery stores across six states, provides a shareholder update highlighting its key growth drivers for 2025, which include operational efficiencies, new revenue streams, investment in key leadership roles and enhanced customer engagement. Healthy Choice Wellness Chairman and CEO Jeff Holman commented, “We are making strategic investments that position HCWC for sustainable growth. By fortifying our team, expanding revenue generation, and enhancing customer engagement, we continue to build a solid foundation for profitability. These initiatives not only drive financial growth...

Continue reading

Biotricity Expands IP Portfolio & Strategy with 14 New Patents, Reinforcing Innovation & Leadership in Remote Monitoring, Diagnostics, & Chronic Disease Management

Biotricity’s latest patents focus on a multi-biometric device platform that functions as both a patch and watch, advancing biometric monitoring solutions for remote patient care. REDWOOD CITY, Calif., March 12, 2025 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB:BTCY), (“Biotricity” or the “Company”), a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce the expansion of its intellectual property (IP) portfolio with 14 new patents. This brings the company’s total to 15 issued patents, with an additional 14 patents pending. The expansion of the company’s IP portfolio underscores Biotricity’s commitment to advancing and improving the patient journey. By streamlining diagnostic processes, Biotricity helps...

Continue reading

FOXO TECHNOLOGIES INC. PROVIDES UPDATE ON ITS BEHAVIORAL HEALTH SUBSIDIARY, MYRTLE RECOVERY CENTERS, INC.

MINNEAPOLIS, MN, March 12, 2025 (GLOBE NEWSWIRE) — FOXO Technologies Inc. (NYSE American: FOXO) (the “Company or FOXO”), provides an update on Myrtle Recovery Centers, Inc., (“Myrtle”) and its behavioral health facility in Oneida, Tennessee, and confirms participation in a major alcohol and drug addiction conference in East Tennessee. Myrtle is pleased to announce that its Oneida, Tennessee substance abuse treatment facility has reached stabilization by maintaining an occupancy rate of 75% or greater since the beginning of 2025. In addition, on occasion, the facility has been at capacity unable to accept additional patients over the same period. Myrtle has also, since the beginning of 2025, finalized a number of in-network contracts with major managed care organizations. Myrtle is also pleased to announce its participation as a...

Continue reading

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received Breakthrough Therapy designation from FDA for MASH Clearance of Investigational New Drug (IND) application for FASN Inhibitor TVB-3567, to be developed for the treatment of acne SAN MATEO, Calif., March 12, 2025 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported financial results for the full year ended December 31, 2024, and provided recent corporate updates. “2024 was a highly productive year for Sagimet, and we’re carrying that momentum into a strong start for 2025,” said David Happel, Chief Executive Officer of Sagimet. “We are pleased to have initiated...

Continue reading

OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial Results

Q4 revenue of $32.3 million, increasing 14% year-over-year Q4 gross profit increased 23% year-over-year to $22.0 million with gross margin of 68% Company generated revenue from 48 DAAP deals in 2024, up from 24 in 2023WALTHAM, Mass., March 12, 2025 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the fourth quarter and full year ended December 31, 2024.  For the Year EndedDecember 31,Key Performance Indicators (KPIs)*   2024       2023    (in thousands, except percentages)Average revenue per top 20 pharmaceutical manufacturer $ 2,933     $ 2,399  Percent of top 20 pharmaceutical manufacturers that are customers   100 %     100 %Percent...

Continue reading

Foremost Clean Energy Announces $6.5 Million Uranium Exploration Program Across the Athabasca Basin

VANCOUVER, British Columbia, March 12, 2025 (GLOBE NEWSWIRE) — Foremost Clean Energy Ltd. (NASDAQ: FMST) (CSE: FAT) (“Foremost” or the “Company”) is pleased to announce its plans for a $6.5 million exploration program in 2025 (the “Program”) across its portfolio of uranium properties in the Athabasca Basin region in northern Saskatchewan. The Program includes the recently announced follow-up drill program on the Hatchet Lake Uranium Property (“Hatchet”) as well as planned exploration on the Murphy Lake South, GR, Blackwing, Wolverine, and CLK properties. Following an initial evaluation of the exploration potential of the 10 properties under option from Denison Mines Corp. (“Denison”)(TSX: DML, NYSE: DNN), Foremost identified several exploration priorities for 2025. The extensive Program will include drilling, geophysical surveys,...

Continue reading

Acumen Pharmaceuticals to Present During International Conference on Alzheimer’s and Parkinson’s Diseases 2025 and American Academy of Neurology Annual Meeting

Oral presentations will highlight the implementation of a validated research-use plasma pTau217 assay in the participant screening process for the Phase 2 ALTITUDE-AD study of sabirnetug NEWTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced upcoming scientific presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) in Vienna, Austria from April 1-5, 2025, and the American Academy of Neurology (AAN) Annual Meeting in San Diego, Calif., from April 5-9, 2025. Oral presentations will focus on implementation of a validated research-use plasma...

Continue reading

Acuity Positioned for Growth and Compounding Value

Rebrands and Introduces New Corporate Identity ATLANTA, March 12, 2025 (GLOBE NEWSWIRE) — Acuity Brands, Inc.’s (NYSE: AYI) corporate name is changing from Acuity Brands, Inc. to Acuity Inc. effective March 26, 2025. Acuity will continue to operate through two business segments, Acuity Brands Lighting (ABL) and Acuity Intelligent Spaces (AIS), formerly Intelligent Spaces Group (ISG). We will continue trading on the New York Stock Exchange under the ticker symbol “AYI”. “Acuity is positioned for long term growth. We are innovators, disruptors and builders who are creating stakeholder value and compounding shareholder wealth,” said Neil Ashe, Chief Executive Officer. “We are using technology to solve problems, redefine industries and create impactful experiences that shape how people live, work and connect.” At Acuity, being an innovator...

Continue reading

Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025

MORRISVILLE, N.C., March 12, 2025 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its full year 2024 financial results on Wednesday, March 19, 2025. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The live webcast will be available on Liquidia’s website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location. About Liquidia CorporationLiquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus...

Continue reading

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)

Trial for this rare genetic disease to be conducted by NIH/NIAID in partnership with Corvus ITK inhibition intended to address dysregulation of T cells that causes ALPS and has been shown to be effective at treating the disease in preclinical models BURLINGAME, Calif., March 12, 2025 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has initiated a Phase 2 clinical trial of soquelitinib for the treatment of patients with autoimmune lymphoproliferative syndrome (ALPS), a rare genetic disease. The lead investigator of the trial is V. Koneti Rao, MD, FRCPA, Senior Research Physician, Primary Immune Deficiency Clinic (ALPS Clinic) at NIH Clinical...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.